<p>Iodixanol nasal solution reduces allergic rhinoconjunctivitis signs and symptoms in Allergen BioCube^&reg;:&nbsp;a randomized clinical trial</p>

Abstract

Purpose Allergic rhinitis (AR) affects ~20% of the population worldwide. The objectives of this study were to evaluate the safety and efficacy of iodixanol nasal solution (Nasapaque) for AR treatment, using the Allergen BioCube ® (ABC ® ), an environmental exposure unit. Iodixanol is a commonly used contrast media agent that shows efficacy on the signs and symptoms of AR. Patients and methods Seventy-three adult subjects with AR were randomized to iodixanol or placebo treatment in a double-masked efficacy and safety study conducted outside of ragweed pollen season. In-office treatment was administered after BioCube ® ragweed pollen exposure, and again 8 days later prior to ragweed exposure. Nasal and ocular efficacy and safety assessments were conducted before and after treatment. Results Iodixanol treatment resulted in statistically significantly lower total nasal symptom scores as compared to placebo at several time points post-treatment and ABC exposure. Individual nasal and ocular symptoms, notably nasal itching and ocular itching, showed evidence of lower scores in the iodixanol group. Peak nasal inspiratory flow (PNIF) improved (9%–16%) with iodixanol from baseline as compared to PNIF in the placebo group which ranged from 3% worsening to improvement of 2%. Few (9) adverse events occurred. Conclusion Iodixanol nasal solution demonstrated efficacy for relief of several nasal and ocular allergic rhinoconjunctivitis signs and symptoms, and was safe and well tolerated in this early Phase II exploratory trial. Further studies with iodixanol are warranted. Allergy challenge models such as the ABC provide valuable assessments of allergen exposures and drug efficacies. Study Identification Number NCT02377895

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

“…In this respect, numerous clinical trials have been conducted using parallel‐group or cross‐over designs in order to test the efficacy of drugs with prophylactic therapeutic potential, such as INCS, 1485–1489 or with immediate therapeutic activity, such as antihistamines 1490–1496 . Novel anti‐inflammatory compounds, 1497–1501 drug‐free nasal fluids, 1502,1503 and probiotics 1504,1505 have also been tested by this method. Additionally, the efficacy of AIT 1506–1517 and air cleaners 1518,1519 has been tested, as well as the influence of allergic nasal symptoms on the absorption of nasally applied drugs 1520 .…”

Deconvolution Analysis of the Non-Ionic Iomeprol, Iobitridol and Iodixanol Contrast Media-Treated Human Whole Blood Thermograms: A Comparative Study

“…Studies comparing the effect of Iodixanol to other iodinated contrast media showed similar or less adverse reactions [29,31,32]. Iodixanol can be applied as an active material of Visipaque in the therapeutic treatment of allergic rhinoconjunctivitis [33]. It can also contribute to the higher purity and longer lifetime of human islet cultures [34].…”